List of Excipients in Branded Drug LEVOFLOXACIN

« Back to Dashboard

Generic Drugs Containing LEVOFLOXACIN

Company	Ingredient	NDC	Excipient
Pharmaceutical Associates Inc	levofloxacin	0121-0872	BENZOIC ACID
Pharmaceutical Associates Inc	levofloxacin	0121-0872	BUTYLATED HYDROXYANISOLE
Pharmaceutical Associates Inc	levofloxacin	0121-0872	FD&C YELLOW NO. 6
Pharmaceutical Associates Inc	levofloxacin	0121-0872	GLYCERIN
Pharmaceutical Associates Inc	levofloxacin	0121-0872	HYDROCHLORIC ACID

What are the Most Frequently-Used Excipients in LEVOFLOXACIN?

# Of NDCs	Excipient
4	ASCORBIC ACID
3	BENZALKONIUM CHLORIDE
2	BENZOIC ACID
4	BENZYL ALCOHOL
2	BUTYLATED HYDROXYANISOLE

Levofloxacin Excipient Strategy, Formulation Patents, and Commercial Opportunities

Last updated: August 20, 2026

Levofloxacin is a mature, low-cost fluoroquinolone with extensive generic competition and limited remaining molecule-level exclusivity. Commercial opportunity is concentrated in differentiated delivery systems, tolerability improvements, preservative-free ophthalmic products, pediatric or hospital-ready presentations, and manufacturing platforms rather than in conventional immediate-release tablets.

The most attractive excipient strategies are those that improve dissolution, reduce photodegradation, support sterile packaging, enable sustained delivery, or address adherence and local tolerability. Basic tablet excipient substitution is unlikely to create durable pricing power because multiple approved generic products already use established direct-compression and wet-granulation platforms.

What is the current FDA and Orange Book status of levofloxacin?

Levofloxacin is an FDA-approved fluoroquinolone antibacterial available in oral, intravenous, and ophthalmic dosage forms. The reference product, Levaquin, was marketed by Ortho-McNeil, later associated with Johnson & Johnson. Generic levofloxacin products are widely approved across tablets, oral solution, injection, and ophthalmic solution categories.

Product category	Typical strength or presentation	FDA pathway	Commercial status
Immediate-release tablets	250 mg, 500 mg, 750 mg	ANDA and legacy NDA products	Highly commoditized
Oral solution	Commonly 25 mg/mL	NDA/ANDA depending on product	Limited but useful for swallowing-impaired patients
IV solution	250 mg/50 mL, 500 mg/100 mL, 750 mg/150 mL	NDA/ANDA	Hospital and outpatient infusion use
Ophthalmic solution	0.5% and 1.5% products	NDA/ANDA	Competitive, with formulation differentiation
Extended-release oral products	Limited historical development	NDA or 505(b)(2)	Commercially difficult

FDA-listed levofloxacin products generally do not carry meaningful remaining new chemical entity exclusivity. The original Levaquin exclusivity and patent period ended years ago. The FDA Orange Book remains relevant for listed patents associated with specific branded products, but the central levofloxacin molecule is no longer protected by an enforceable composition-of-matter barrier in the United States. FDA Orange Book listings must be evaluated product by product because listed patents can relate to formulations, delivery systems, or approved methods of use rather than the active ingredient itself (U.S. Food and Drug Administration [FDA], n.d.-a).

When did levofloxacin lose exclusivity and patent protection?

Levofloxacin’s core patent and regulatory exclusivity expired long before the current generic market formed. The original U.S. patent estate was associated with levofloxacin as the optically active form of ofloxacin and with related quinolone chemistry. The practical result is that generic manufacturers can compete on the active ingredient without licensing the original innovator.

Protection category	Status	Commercial implication
Levofloxacin composition-of-matter protection	Expired	No active molecule-level barrier
Original Levaquin regulatory exclusivity	Expired	ANDA competition permitted
Standard immediate-release tablet claims	Generally expired or commercially weak	Low barrier to entry
IV solution formulation claims	Largely mature	Manufacturing and procurement scale matter more
Ophthalmic formulation claims	Product-specific and potentially active	Greater opportunity for differentiated products
New delivery or combination claims	Potentially available	Requires new clinical and regulatory support

A precise patent-expiration analysis must distinguish the original levofloxacin patent from later patents covering specific formulations or delivery technologies. A patent search should include U.S. Patent and Trademark Office records, FDA Orange Book entries, international patent families, and post-grant status. Patent expiration can also be affected by patent-term adjustment, patent-term extension, terminal disclaimers, and abandonment.

What excipients are used in commercial levofloxacin products?

Commercial formulations use conventional pharmaceutical excipients selected for manufacturability, dissolution, stability, sterility, and route-specific tolerability.

Oral tablets

Representative generic levofloxacin tablets commonly use some combination of:

• Microcrystalline cellulose as a diluent and compression aid
• Crospovidone or croscarmellose sodium as a superdisintegrant
• Hypromellose as a film-forming polymer
• Magnesium stearate as a lubricant
• Colloidal silicon dioxide as a flow aid
• Polyethylene glycol and titanium dioxide in the film coating
• FD&C colorants or iron oxides for product identification

The primary formulation risk is not basic tablet manufacture. It is maintaining rapid and reproducible dissolution across strengths while controlling polymorphic form, particle size, blend uniformity, and compression force. Levofloxacin is generally soluble enough for immediate-release oral products, but formulation performance can be affected by pH, solid-state properties, and interaction with multivalent cations.

Oral solution

Oral solutions may use purified water, pH adjusters, buffers, sweeteners, flavors, and viscosity modifiers. The principal development issues are:

1. Chemical stability over the labeled shelf life.
2. Taste masking.
3. Compatibility with dosing syringes and measuring devices.
4. Control of precipitation during storage.
5. Pediatric acceptability.

Taste masking has commercial relevance because the bitter profile of fluoroquinolones can reduce adherence, particularly in pediatric and swallowing-impaired populations. Ion-exchange resins, cyclodextrins, polymeric taste-masking systems, and multiparticulate suspensions may support differentiated products, although each can affect dissolution and bioavailability.

Intravenous products

IV levofloxacin commonly uses sodium chloride solution or dextrose-containing vehicles, with pH adjustment where required. The formulation must control:

• Particulate matter
• Container-closure compatibility
• Light exposure
• Precipitation risk
• Infusion-line compatibility
• Sterility and endotoxin levels

Ready-to-administer bags and pharmacy-prepared premixes can reduce preparation steps and medication errors. These products compete on procurement contracts, shelf life, packaging, supply reliability, and nursing workflow rather than on active-ingredient novelty.

Ophthalmic solutions

Ophthalmic levofloxacin products may contain sodium chloride, glycerin or other tonicity agents, purified water, pH adjusters, and preservatives such as benzalkonium chloride depending on the product. Preservative-free single-dose packaging creates a differentiated opportunity for patients requiring repeated dosing or with ocular-surface sensitivity.

Ophthalmic formulation work must address sterility, osmolality, viscosity, drop size, container extractables and leachables, preservative efficacy where applicable, and patient comfort. A preservative-free product may support a 505(b)(2) strategy if the sponsor can establish a clinically and commercially meaningful difference from existing products.

What excipient strategies offer the strongest commercial opportunities?

1. Preservative-free ophthalmic delivery

Preservative-free levofloxacin eye drops are one of the clearer formulation opportunities. The product can target:

• Patients with ocular-surface disease
• Postoperative ophthalmic care
• High-frequency dosing
• Preservative intolerance
• Institutional and surgical-center use

Unit-dose vials increase packaging cost and manufacturing complexity. The commercial case depends on reimbursement, premium pricing, supply reliability, and evidence that clinicians will switch from low-cost multidose products.

2. Taste-masked oral liquid

A palatable oral liquid could address pediatric and geriatric use, but levofloxacin’s safety profile limits routine pediatric use to specific indications. A sponsor would need to align the product with approved populations and labeling. Taste masking can use ion-exchange resins, cyclodextrins, coated microparticles, or flavor systems. The strongest value proposition is improved administration and adherence, not broader clinical use.

3. Ready-to-use IV bags

Premixed IV presentations can reduce hospital compounding requirements. A differentiated product may use:

• Improved oxygen and light barriers
• High-clarity multilayer bags
• Extended in-use stability
• Standardized concentrations
• Closed-system transfer compatibility

The principal barrier is operational scale. Hospital buyers often select products through group purchasing organizations, tenders, and shortage-management criteria. A technically superior excipient system will not overcome an unreliable supply chain.

4. Modified-release oral products

Sustained-release levofloxacin could reduce dosing frequency and peak-related adverse effects, but this strategy has substantial clinical and regulatory risk. Fluoroquinolone efficacy is linked to pharmacokinetic and pharmacodynamic exposure parameters, including area under the curve to minimum inhibitory concentration and peak concentration to minimum inhibitory concentration. A modified-release product must preserve target exposure and avoid subtherapeutic concentrations that could promote treatment failure or resistance.

A 505(b)(2) application could be possible for a materially different dosage form, but clinical pharmacology, food-effect, safety, and efficacy requirements may eliminate the economic advantage.

5. Amorphous or nanostructured solid dispersions

Solubility-enhancing systems can use polymers such as hydroxypropyl cellulose, hydroxypropyl methylcellulose acetate succinate, or povidone. These approaches may improve dissolution or enable lower-dose products, but they have limited value for conventional levofloxacin tablets unless they solve a demonstrated absorption or stability problem.

The best use case is a new delivery route, combination product, or long-acting platform. For standard oral levofloxacin, added formulation complexity may increase cost without creating a strong clinical advantage.

What formulation patents can protect levofloxacin products?

Formulation patents may protect a defined composition, manufacturing process, dosage form, packaging system, or performance profile. Potential claim categories include:

Patent category	Example claim focus	Relative commercial value
Excipient composition	Specific polymer, buffer, surfactant, or preservative ratio	Moderate if difficult to design around
Solid-state formulation	Particle size, polymorph, amorphous dispersion	Moderate to high if linked to performance
Ophthalmic system	Preservative-free, low-irritation, multidose sterile delivery	High if clinically differentiated
Taste masking	Coated particles, resin complex, flavor system	Moderate
Modified release	Matrix, coating, osmotic system, multiparticulate profile	High but technically risky
IV packaging	Bag material, oxygen barrier, premix stability	Moderate
Manufacturing process	Mixing, granulation, sterilization, or filling sequence	Variable
Method of use	Dosing regimen or specific infection	Narrow and vulnerable to clinical-label limits

A patent directed only to routine excipient substitution is vulnerable to obviousness challenges. Stronger protection links the excipient system to an unexpected result, such as improved stability, reduced ocular irritation, controlled release, lower impurity formation, or a defined pharmacokinetic profile.

How strong is the current levofloxacin patent estate?

The overall estate is weak for unmodified levofloxacin and stronger only in selected delivery niches. The molecule is generic, the reference product has lost exclusivity, and conventional tablets have little practical protection.

Segment	Patent strength	Entry risk
Immediate-release tablets	Low	Low
Standard oral solution	Low to moderate	Low
Generic IV solution	Low to moderate	Low
Preservative-free ophthalmic product	Moderate	Moderate
Modified-release oral product	Potentially high	Moderate to high
Novel sterile packaging	Moderate	Moderate
Combination or device-enabled product	Product-specific	Moderate to high

The key risk is not usually a Paragraph IV challenge to the original molecule. It is freedom-to-operate exposure against later patents covering a branded ophthalmic product, delivery device, manufacturing process, or combination therapy.

Which companies are competing in levofloxacin generics?

Levofloxacin is supplied by numerous generic manufacturers and contract manufacturers. The competitive field has included large U.S. generic companies, global pharmaceutical manufacturers, and regional suppliers. Product-level availability changes because of discontinuations, shortages, procurement decisions, and manufacturing transfers.

Competition is based on:

• Approved strengths and dosage forms
• ANDA status
• Manufacturing reliability
• Contract pricing
• Hospital formulary access
• Shortage history
• Product discontinuation risk
• Packaging and distribution capacity

A new entrant faces low technical barriers for standard tablets but significant commercial barriers. A filing alone does not create durable share in a mature antibiotic market.

Are there Paragraph IV challenges, biosimilar risks, or active litigation?

Levofloxacin is a small-molecule drug, so biosimilar regulation does not apply. Competition proceeds through the ANDA pathway, not the biosimilar pathway.

Historical Paragraph IV activity was relevant when Levaquin patents remained enforceable. That period has passed for the original product estate. Current development programs should focus on later-listed patents associated with specific branded formulations or delivery systems rather than assume that all levofloxacin products are unprotected.

No active, material litigation status should be inferred solely from the existence of historical Levaquin patent disputes. A live litigation review requires current court dockets, Orange Book listings, patent assignment records, and product-specific notices. The principal legal exposure for a new excipient product is likely to be formulation-patent infringement or regulatory exclusivity, not the expired core levofloxacin patent.

What is the revenue opportunity for differentiated levofloxacin products?

Standard levofloxacin tablets offer limited revenue upside because generic prices are compressed and substitution is common. Higher-value opportunities are concentrated in products that remove a hospital workflow burden or address a specific tolerability problem.

Opportunity	Revenue potential	Main constraint
Commodity tablets	Low	Price competition
Premium oral liquid	Moderate	Limited eligible population
Preservative-free ophthalmic drops	Moderate to high	Packaging and reimbursement
Ready-to-use IV bags	Moderate	Hospital contracting
Modified-release tablets	High if clinically successful	Development and regulatory cost
Specialty device combination	High but uncertain	Device, clinical, and patent complexity

Revenue exposure to an incumbent manufacturer is highest in IV and ophthalmic products where supply continuity and formulation-specific approval matter. Exposure is lower in ordinary tablets because alternative suppliers are abundant.

What is the best commercial excipient strategy for levofloxacin?

The strongest near-term strategy is a focused ophthalmic or hospital product rather than another standard oral tablet. A practical development sequence is:

1. Select a route with a clear clinical or workflow problem.
2. Use excipients with established FDA safety histories and relevant inactive-ingredient precedents.
3. Establish a measurable performance advantage, such as preservative elimination, improved stability, reduced irritation, or extended in-use dating.
4. Design claims around the composition, process, packaging, and measurable product attributes.
5. Build freedom-to-operate coverage around branded competitors and known delivery platforms.
6. Use a 505(b)(2) or ANDA pathway based on the degree of formulation and clinical difference.
7. Secure manufacturing capacity before seeking hospital or specialty-pharmacy contracts.

Key Takeaways

• Levofloxacin’s core composition-of-matter and original Levaquin exclusivity have expired.
• Conventional immediate-release tablets are commercially commoditized.
• Biosimilar risk does not apply because levofloxacin is a small molecule.
• The most attractive excipient opportunities are preservative-free ophthalmic products, taste-masked oral liquids, ready-to-use IV bags, and selected modified-release systems.
• Formulation patents are strongest when tied to unexpected stability, tolerability, pharmacokinetic, or manufacturing results.
• Generic entry risk is low for ordinary tablets and higher for differentiated ophthalmic, device-enabled, and modified-release products.
• Commercial success depends more on procurement access, supply reliability, packaging, and route-specific differentiation than on active-ingredient exclusivity.

FAQs

Can a new levofloxacin tablet obtain meaningful patent protection through excipient selection?

Usually not by routine substitution alone. Protection is more defensible when the excipient system produces an unexpected technical result and the claims define a non-obvious composition or performance range.

Is a levofloxacin preservative-free eye drop eligible for a 505(b)(2) application?

Potentially. The pathway depends on the extent of formulation and packaging differences, the reference product selected, and the clinical evidence required to support the proposed labeling.

Which levofloxacin dosage form has the best margin potential?

Preservative-free ophthalmic products and ready-to-use IV presentations generally offer better differentiation than standard tablets. Margin depends on packaging cost, reimbursement, contracting, and supply reliability.

Do levofloxacin formulations need protection against biosimilar competition?

No. Levofloxacin is regulated as a small-molecule drug. Competitive entry occurs through ANDAs and, for certain reformulations, potentially through an NDA or 505(b)(2) application.

What manufacturing barriers matter most for levofloxacin excipient products?

Sterile filling, container-closure qualification, preservative-free packaging, light protection, particulate control, and validated stability are the main barriers for ophthalmic and IV products. Tablet manufacturing has far lower entry complexity.

References

1. U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

2. U.S. Food and Drug Administration. (n.d.-b). DailyMed: Levofloxacin drug labels. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/

3. U.S. Food and Drug Administration. (2017). Application number 019847: Levaquin NDA approval history. https://www.accessdata.fda.gov/drugsatfda_docs/label/

4. U.S. Food and Drug Administration. (2019). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/

5. U.S. Food and Drug Administration. (2024). Approved drug products and abbreviated new drug applications. https://www.fda.gov/drugs/generic-drugs

6. U.S. Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/

7. National Library of Medicine. (n.d.). Levofloxacin. MedlinePlus. https://medlineplus.gov/druginfo/meds/a697040.html